JP2022511096A5 - - Google Patents

Info

Publication number
JP2022511096A5
JP2022511096A5 JP2021532209A JP2021532209A JP2022511096A5 JP 2022511096 A5 JP2022511096 A5 JP 2022511096A5 JP 2021532209 A JP2021532209 A JP 2021532209A JP 2021532209 A JP2021532209 A JP 2021532209A JP 2022511096 A5 JP2022511096 A5 JP 2022511096A5
Authority
JP
Japan
Prior art keywords
present
antibody
cancer
caf
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065008 external-priority patent/WO2020118216A1/en
Publication of JP2022511096A publication Critical patent/JP2022511096A/ja
Publication of JP2022511096A5 publication Critical patent/JP2022511096A5/ja
Pending legal-status Critical Current

Links

JP2021532209A 2018-12-08 2019-12-06 がんおよび他の疾患の診断および処置のための腫瘍促進がん関連線維芽細胞の同定および標的化 Pending JP2022511096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777101P 2018-12-08 2018-12-08
US62/777,101 2018-12-08
PCT/US2019/065008 WO2020118216A1 (en) 2018-12-08 2019-12-06 Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases

Publications (2)

Publication Number Publication Date
JP2022511096A JP2022511096A (ja) 2022-01-28
JP2022511096A5 true JP2022511096A5 (cg-RX-API-DMAC7.html) 2024-03-05

Family

ID=70973537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021532209A Pending JP2022511096A (ja) 2018-12-08 2019-12-06 がんおよび他の疾患の診断および処置のための腫瘍促進がん関連線維芽細胞の同定および標的化

Country Status (8)

Country Link
US (1) US20220144938A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890802A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511096A (cg-RX-API-DMAC7.html)
KR (1) KR20210102331A (cg-RX-API-DMAC7.html)
CN (1) CN113412130A (cg-RX-API-DMAC7.html)
AU (1) AU2019392915B2 (cg-RX-API-DMAC7.html)
CA (1) CA3121933A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020118216A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
WO2021158966A1 (en) 2020-02-05 2021-08-12 Board Of Regents, The University Of Texas System Diagnostic and prognostic utility of exosomes in immunotherapy
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
CN114529541A (zh) * 2022-03-28 2022-05-24 中国人民解放军海军军医大学第一附属医院 预测胰腺癌微环境中细胞表达的方法、电子设备、介质及系统
CN114533884A (zh) * 2022-04-20 2022-05-27 澳门大学 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用
WO2025242065A1 (zh) * 2024-05-23 2025-11-27 苏州易慕峰生物科技有限公司 一种预测实体瘤免疫细胞疗法治疗应答的方法
CN119570741A (zh) * 2024-12-20 2025-03-07 江苏亲科生物研究中心有限公司 一种wdr89单克隆抗体及其试剂盒的制备方法和用途
CN119735640A (zh) * 2024-12-23 2025-04-01 中国人民解放军空军军医大学 Ms4a6c抗原表位肽、抗原、抗体、杂交瘤细胞株及用途
CN121856553B (zh) * 2026-03-19 2026-06-30 南通大学附属医院 Hnrnpf的k224乳酸化修饰作为靶点在制备用于胰腺癌诊断和/或治疗的产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
JP5904552B2 (ja) * 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
CN107531773A (zh) * 2015-03-11 2018-01-02 俄勒冈州普罗维登斯健康与服务部 用于增强癌症治疗的效果的组合物和方法
WO2017040686A1 (en) * 2015-09-01 2017-03-09 University Of Miami Identification of circulating cancer associated fibroblasts
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
EP3484455A2 (en) * 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor

Similar Documents

Publication Publication Date Title
US20250368737A1 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
AU2023237216A1 (en) BCMA And CD3 Bispecific T Cell Engaging Antibody Constructs
AU2018295119B2 (en) Multi-specific antibodies and methods of making and using thereof
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
JP6682426B2 (ja) 抗b7−h5抗体およびその使用
US12252546B2 (en) Anti-SIRPa antibodies and their therapeutic applications
EP3645742A2 (en) Anti-ror1 antibodies and methods of making and using thereof
TW201803899A (zh) 三特異性和/或三價結合蛋白
TW202221021A (zh) 改良之抗原結合受體
KR20210149141A (ko) 삼중특이적 결합 단백질, 이의 방법 및 용도
WO2021216468A1 (en) Human tigit specific single domain antibodies and methods of use
TWI833244B (zh) 一種雙抗組合及其應用
JP2022534212A (ja) 免疫チェックポイント阻害剤と組み合わせてsirpアルファfc融合によりがんを治療する方法
JP2024123004A (ja) エキソソーム標的化二重特異性抗体
CN117279950B (zh) 一种靶向il-18bp的抗体及其应用
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
TW202118784A (zh) 抗bcma藥劑之給藥方案
KR20230104229A (ko) Cd3에 결합하는 폴리펩티드 구축물
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防
WO2025061050A1 (en) Antibodies targeting ctla4 and cd47 and uses thereof
EP4011918A1 (en) Dual-specific protein
CN121079322A (zh) 抗cd27单克隆抗体及其应用
WO2024193668A1 (zh) 抗ctla-4/抗tigit双特异性抗体及其应用
EA051364B1 (ru) Улучшенные антигенсвязывающие рецепторы
WO2021170146A1 (zh) 新型抗cd19抗体和cd19-car-t细胞的制备及其应用